Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Explaining It All | Main | Summer Student Time »

May 13, 2008

In Which I Hate A Wonder Drug

Email This Entry

Posted by Derek

Schering-Plough has had its share of troubles over the years, but the company has also seen itself saved by some pretty unlikely compounds. Vytorin (ezetimibe) is the example I’ve spoken about here, and if the drug doesn’t seem like a savior at the moment, well, you have to keep in mind that it was the biggest thing for them since Claritin went off-patent ten years ago.

Now there’s another one potentially coming up. Expectations are building for a thrombin receptor antagonist compound, SCH 530348. And I have a history with this one, too: while the labs down one hallway from me were discovering ezetimibe, down the other hallway they were laying the foundation for this one. There’s a big difference, though, in the way I saw the two.

This thrombin antagonist is an unlikely drug for several reasons. For one thing, its structure is not the sort of thing most medicinal chemists would go out of their way to make. But there’s a good reason for that: to a first approximation, it wasn’t made with medicinal chemistry in mind. 530348 is based on a natural product called himbacine, whose fame, such as it is, rests on its properties as a semi-selective muscarinic antagonist. And that’s how Schering-Plough got interested in this class of compounds; thrombin had nothing to do with it.

At the time (early to mid 1990s) the company had a team working on Alzheimer’s disease, and I’ll go ahead and mention again that I was one of the people involved. (Five minutes on SciFinder would tell you that, anyway). We were quite interested in selective muscarinic antagonists, particularly for the m2 subtype, and himbacine was at the time one of the more selective compounds with that profile. So one of the group leaders at the company, Sam Chackalamannil, decided to synthesize it and do some SAR around the structure.

That was no small undertaking. Himbacine’s not one of the most complex natural products by any means, but it’s no stroll to the beach, either, especially when compared to the usual sorts of drug structures. It took a lot of time, a lot of ingenuity, and (most importantly) a lot of effort to do it. And I. . .well, I thought this was a terrible idea.

I really did. By the time himbacine itself got made, the project team had muscarinic compounds that were more selective and more potent (and a lot easier to make, to boot). I would listen to Chackalamannil’s people presenting their long, difficult routes during meetings, and I’d sit there imagining the company going slowly bankrupt if everyone adopted this approach, the revenue slowly sinking as the number of JACS communications rose. I couldn’t see the point, and although I don’t think I ever quite had the nerve to say so to Chackalamannil himself (hi, Sam!), I said it to plenty of other people.

So, is it time for me to eat crow? Well, one plateful, at least. Some of the himbacine analogs hit in the high-throughput screen for thrombin activity, to everyone’s surprise, and some further compounds (now shed of their muscarinic activity) were even better. The drug discovery effort culminated in 530548, which now might be about to benefit a huge number of people and make the company a ton of money, if everything goes well.

Of course, if these things hadn’t hit in the thrombin assay, I could have remained secure in my opinion. After all, they were never worth very much as muscarinics, as far as I know. (Of course, our muscarinic compounds, in the end, never were worth very much as Alzheimer’s drugs, which is something to keep in mind). So that’s the question: how likely is it for molecules like this to work? It’s very hard to answer that, but given this data point, I guess the answer is “at least a little more likely than I thought”. The very fact that they didn’t look like most other things in the screening deck was probably in their favor. I still think that these compounds were a long shot, but this is a business that lives on long shots. This one came through, and congratulations to everyone involved.

Comments (8) + TrackBacks (0) | Category: Alzheimer's Disease | Cardiovascular Disease | Drug Development


COMMENTS

1. Nick K on May 13, 2008 9:31 AM writes...

Hats off to the chemists who made Himbacine, and to a very brave management. Once again, this saga illustrates the importance of serendipity in drug discovery.

Permalink to Comment

2. Jack Friday on May 13, 2008 3:06 PM writes...

How convenient - just when the wheels fall of the Vytorin waggon another hopeful appears over the horizon.

Call me an old sceptic........

Permalink to Comment

3. Derek Lowe on May 13, 2008 3:18 PM writes...

OK, JF, you're an old sceptic.

Actually, this compound has been in the works for years. These showed potential thrombin activity back around the time I left Schering-Plough, which has been years ago. That would make it about six or seven years past the discovery of ezetimibe, and allowing for that compound's difficult birth, that's just about right on target.

Permalink to Comment

4. milkshake on May 13, 2008 7:00 PM writes...

I just looked up their JACS paper on total synthesis of (+)-Himbacine and it is very nice.

I think Himbacine is reasonable as a natural compound-derived scaffold, it does not have any funky groups and the Diels-Alder approach fairly modular. The only complaint is that the molecule looks somewhat greasy. But many statins and steroids are funkier. (Acetylene-containing contraceptives for example!) I agree that cranking out biaryls by Suzuki reaction is faster - yet sometimes you get lucky with not-so-simple compounds.

Permalink to Comment

5. PorkPieHat on May 13, 2008 8:53 PM writes...

As drug companies divest of natural products, the industry loses opportunities from "the wisdom of the ages" that is the serindipity to which Nick K refers. If you and I ever meet, D.Lowe, you'll have to ask me about another "Himbacine analog" - like story that is a billion$ drug today. If SOME fraction of medicinal chemists are not permitted the freedom to do what Chackalamannil did within our industry, we don't benefit from this high-risk high reward activity.

Permalink to Comment

6. Panoramix on May 14, 2008 1:12 AM writes...

The molecule looks like a hybrid, the southern part is totally artificial and the northern part is pure total synthesis of natural products.

Permalink to Comment

7. RTW on May 14, 2008 11:40 AM writes...

As a 20 year medicinal chemist I have worked on unlikely structures like this myself. In Anticancer drug design much was derived from difficult to prepare natural products. VP-16, Tenopiside, Campothecin, Mitomycin-C, its not unprecedented at least in Anti-bacterials, Anti-Cancer Agents and Anti virals, though even in these areas more "traditional" heterocycles are taking their place...

I have to agree also that these seem very unlikely in CNS, and CV therapies. But one must remember that Mevacor started out as complex natural product as well.

At any rate - For the actual chemists in the group. I found a C&EN article that contains a nice blurb and the structure.

http://pubs.acs.org/email/cen/html/021806150931.html

Enjoy.

Permalink to Comment

8. vm ganata on May 21, 2008 11:12 AM writes...

Well, in med school pharmacology, they love to repeat the story of Fleming's serendipitous discovery of penicillin. I'm not surprised not much has changed in terms of drug discovery.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
What If?
Novartis Impresses Where Others Have Failed
Exelixis Against the Wall
A Last Summer Day Off
The Early FDA
Drug Repurposing
The Smallest Drugs
Life Is Too Short For Some Journal Feeds